ALLMedicine™ Thrombotic Thrombocytopenic Purpura Center
Research & Reviews 2,255 results
https://doi.org/10.1186/s13256-020-02577-5 10.1056/NEJMra1312353 10.1111/j.1365-2141.2012.09167.x 10.1111/j.1365-2141.2005.05837.x 10.1097/01.AOG.0000258281.22296.de 10.1046/j.1526-0968.2002.00390.x 10.3324/haematol.2011.051433 10.1016/S0140-6736(20)30360-3 10.1111/aji.12355 10.1093/cid/ciw412 10.1093/cid/ciaa200 10.1016/j.tmaid.2020.101665 10.3390/v12020194 10.1016/j.jinf.2020.02.028 10.1055/s-0032-1331380 10.4103/joacc.JOACC_10_19 10.1160/TH03-11-0683 10.1097/AOG.0b013e31828e2612 10.1016/j.transci.2015.11.005 10.1016/j.ajog.2003.11.019
Journal of Medical Case Reports; Aminimoghaddam S, Afrooz N et. al.
Mar 2nd, 2021 - Pregnancy seems to increase the risk of thrombotic thrombocytopenic purpura (TTP) relapses and make the TTP more severe in any of the pregnancy trimesters, or even during the postpartum period. This study highlights details of treating a COVID-19 ...
https://doi.org/10.1182/blood.2020009801
Blood Tarasco E, Bütikofer L et. al.
Mar 2nd, 2021 - Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare thrombotic microangiopathy characterized by severe congenital ADAMTS13 deficiency and recurring acute episodes causing morbidity and premature death. Information on the annual inciden...
https://doi.org/10.3324/haematol.2020.278244
Haematologica Hrdinová J, D'Angelo S et. al.
Mar 1st, 2021 - Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.|2021|Hrdinová J,D'Angelo S,Graça NAG,Ercig B,Vanhoorelbeke K,|
https://doi.org/10.1016/j.ajog.2021.02.018
American Journal of Obstetrics and Gynecology; Miodownik S, Pikovsky O et. al.
Feb 23rd, 2021 - Thrombotic Thrombocytopenic Purpura (TTP), a rare, potentially life-threatening thrombotic microangiopathy, manifests as both congenital (cTTP) and acquired forms. It is caused by the absence of or severe depletion in a disintegrin and metalloprot...
https://doi.org/10.1007/s40620-021-00992-5 10.1182/blood-2016-10-709857 10.1080/17474086.2019.1611423 10.1002/rth2.12160 10.1056/NEJMoa1505533 10.1056/NEJMoa1806311 10.1002/pbc.27737 10.1002/pbc.28534 10.1007/s00467-019-04281-z 10.1016/j.lpm.2019.08.024 10.1016/S2352-3026(16)30125-9 10.1111/ejh.13107 10.1182/blood.2020008021 10.1182/blood.2020007599
Journal of Nephrology; Boudali J, Hallak B et. al.
Feb 22nd, 2021 - Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunatel...
Guidelines 11 results
http://products.sanofi.us/cablivi/cablivi.pdf
Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
https://www.healio.com/hematology-oncology/hematology/news/online/%7Be91d83f6-8859-412b-970c-198151f0b208%7D/fda-approves-cablivi-first-treatment-for-acquired-thrombotic-thrombocytopenic-purpura
Pazdur,R.
Feb 5th, 2019 - The FDA today approved caplacizumab-yhdp injection as the first therapy specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting disorder.
http://hugin.info/152918/R/2233733/878824.pdf
Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the firs...
https://www.nejm.org/doi/10.1056/NEJMoa1806311
Scully,M.,et al
Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which re...
https://www.jwatch.org/na48305/2019/01/17/caplacizumab-acquired-thrombotic-thrombocytopenic-purpura
Green,David
Jan 16th, 2019 - Patients with acquired thrombotic thrombocytopenic purpura (TTP) have von Willebrand factor (VWF)–mediated platelet aggregates that ...HERCULES Trial
Drugs 13 results see all →
Clinicaltrials.gov 2,307 results
https://doi.org/10.1186/s13256-020-02577-5 10.1056/NEJMra1312353 10.1111/j.1365-2141.2012.09167.x 10.1111/j.1365-2141.2005.05837.x 10.1097/01.AOG.0000258281.22296.de 10.1046/j.1526-0968.2002.00390.x 10.3324/haematol.2011.051433 10.1016/S0140-6736(20)30360-3 10.1111/aji.12355 10.1093/cid/ciw412 10.1093/cid/ciaa200 10.1016/j.tmaid.2020.101665 10.3390/v12020194 10.1016/j.jinf.2020.02.028 10.1055/s-0032-1331380 10.4103/joacc.JOACC_10_19 10.1160/TH03-11-0683 10.1097/AOG.0b013e31828e2612 10.1016/j.transci.2015.11.005 10.1016/j.ajog.2003.11.019
Journal of Medical Case Reports; Aminimoghaddam S, Afrooz N et. al.
Mar 2nd, 2021 - Pregnancy seems to increase the risk of thrombotic thrombocytopenic purpura (TTP) relapses and make the TTP more severe in any of the pregnancy trimesters, or even during the postpartum period. This study highlights details of treating a COVID-19 ...
https://doi.org/10.1182/blood.2020009801
Blood Tarasco E, Bütikofer L et. al.
Mar 2nd, 2021 - Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare thrombotic microangiopathy characterized by severe congenital ADAMTS13 deficiency and recurring acute episodes causing morbidity and premature death. Information on the annual inciden...
https://doi.org/10.3324/haematol.2020.278244
Haematologica Hrdinová J, D'Angelo S et. al.
Mar 1st, 2021 - Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.|2021|Hrdinová J,D'Angelo S,Graça NAG,Ercig B,Vanhoorelbeke K,|
https://doi.org/10.1016/j.ajog.2021.02.018
American Journal of Obstetrics and Gynecology; Miodownik S, Pikovsky O et. al.
Feb 23rd, 2021 - Thrombotic Thrombocytopenic Purpura (TTP), a rare, potentially life-threatening thrombotic microangiopathy, manifests as both congenital (cTTP) and acquired forms. It is caused by the absence of or severe depletion in a disintegrin and metalloprot...
https://doi.org/10.1007/s40620-021-00992-5 10.1182/blood-2016-10-709857 10.1080/17474086.2019.1611423 10.1002/rth2.12160 10.1056/NEJMoa1505533 10.1056/NEJMoa1806311 10.1002/pbc.27737 10.1002/pbc.28534 10.1007/s00467-019-04281-z 10.1016/j.lpm.2019.08.024 10.1016/S2352-3026(16)30125-9 10.1111/ejh.13107 10.1182/blood.2020008021 10.1182/blood.2020007599
Journal of Nephrology; Boudali J, Hallak B et. al.
Feb 22nd, 2021 - Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunatel...
News 107 results
https://www.medscape.com/viewarticle/941022
Nov 15th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...
https://www.mdedge.com/jcomjournal/article/211340/mixed-topics/2019-glance-hem-onc-us-drug-approvals/page/0/1?channel=325
Oct 31st, 2019 - Caplacizumab-yhdp (Cablivi) Class: Monoclonal antibody fragment directed against von Willebrand factor. Disease: Thrombotic thrombocytopenic purpura.
https://www.mdedge.com/hematology-oncology/article/209753/bleeding-disorders/older-patients-immune-mediated-ttp-atypical?channel=39313
Andrew D. Bowser
Oct 9th, 2019 - Older patients with immune thrombotic thrombocytopenic purpura (iTTP) more often have an atypical neurological presentation, which could result in a delayed diagnosis, according to authors of a recent retrospective analysis. “Practitioners should.
https://www.mdedge.com/internalmedicine/article/199586/bleeding-disorders/ttp-death-linked-elevated-troponin-and?channel=285
Will Pass
Apr 25th, 2019 - GLASGOW – Neurological abnormalities and elevated troponin predict mortality in patients with thrombotic thrombocytopenic purpura (TTP), according to retrospective analysis of 475 patients from the United Kingdom TTP registry. Will Pass/MDedge New.
https://www.staging.medscape.com/viewarticle/911288
Apr 3rd, 2019 - GLASGOW — Combining prophylactic infusions and anti-platelet therapy normalises thrombus formation in patients with congenital thrombotic thrombocytopenic purpura (TTP) under shear flow conditions, reveals a novel assay developed by UK researchers...